Delivery systems, compositions, and methods for forming and delivering biomaterials from two components are described. Specifically, a composition includes a first component and a second component that are each formulated to be crosslinked with the other to form a hydrogel. The first component and the second component are formulated to have an initial storage modulus (initial G) and an initial loss modulus (initial G″) when initially combined such that a ratio of the initial G″ to the initial G is between about 5 and about 100. The first component and the second component are formulated to have a gelation storage modulus (gelation G) and a gelation loss modulus (gelation G″) at a gelation time after the first component and the second component are combined such that a atio of the gelation G″ to the gelation G is less than about 1. The gelation time is less than about 120 seconds.

This document provides materials and methods for permanent arterial embolization and/or enhanced vascular healing. For example, materials and methods for using bioactive tissue derived nanocomposite hydrogels to enhance vascular healing are provided.

The invention generally relates to cells and compositions comprising same for use in cell therapy, to methods of obtaining same, and to use of same in cell therapy. In one aspect, the invention provides a method for forming a cell composition from a tissue sample, the method comprising: providing a tissue sample comprising cells; contacting the sample with a polymer in binding conditions, said binding conditions being conditions that enable binding of cells in the sample to the polymer, so that said cells are bound to the polymer; culturing the cells bound to the polymer under conditions and for a time that allows the cell number to increase; providing conditions to induce a phase change of the polymer; thereby forming a cell composition from a tissue sample.

The present invention relates to a process for preparing a crosslinked gel of at least one polysaccharide or a salt thereof, comprising at least the steps consisting in: a) providing a solution formed from an aqueous medium comprising at least said polysaccharide(s) or a salt thereof in a non-crosslinked form, at least one difunctional or multifunctional epoxide crosslinking agent chosen from butanediol diglycidyl ether, diepoxyoctane, 1,2-bis(2,3-epoxypropyl)-2,3-ethylene, and mixtures thereof, and at least one phosphate salt; b) crosslinking the solution from step a) and, where appropriate; c) recovering said crosslinked gel formed.

Described herein are methods that result in less cell death resulting from myocardial infarction than would otherwise occur in an individual who has suffered myocardial infarction. Also described are compositions useful in reducing cell death post myocardial infarction.

Described herein are compositions of alginate formulations and their use for treating incisional wounds, such as intra-incisional application.

Compositions and methods for glass composites suitable for tissue augmentation, biomedical, and cosmetic applications are provided. The glass microsphere component of the composites are biologically inert, non-reactive and act as a nearly permanent tissue filler. One embodiment provides a tissue augmentation composite containing an effective amount of solid glass microspheres, hollow glass microspheres, porous wall hollow glass microspheres, or combinations thereof with a suitable biocompatible matrix to serve as a bulking agent when injected into a patient. The compositions can be used for soft or hard tissue augmentation as well as delivery of cargos on demand.

The present disclosure relates to hydrogels and their use for repairing or supplementing body tissue. The hydrogels are capable of safe injection into patients through fine gauge needles and are suitable for repairing, supplementing, or replacing the nucleus pulposus of an intervertebral disc. Methods of manufacturing and methods of using the hydrogels of the present disclosure to repair or replace tissues are also disclosed.

Hyaluronic acid and silk protein fragments based tissue fillers and methods of the same are provided herein.

The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.